Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Eimermacher · SciRah

Researcher profile · Semantic Scholar

H. Eimermacher

Share profile

H. Eimermacher — researcher profile on SciRah

h-index: 23
Works: 68
Citations: 5,796

Most-cited papers

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits +22 more
2008The Lancet Oncology1,097 citations
Semantic Scholar
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
E. Hoster, M. Dreyling, W. Klapper, C. Gisselbrecht +16 more
2006Blood980 citations
Semantic Scholar
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t
W. Hiddemann, Michael Kneba, M. Dreyling, Norbert Schmitz +19 more
2005Blood777 citations Open access
Semantic Scholar
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
M. Pfreundschuh, L. Trumper, M. Kloess, R. Schmits +9 more
2004Blood746 citations Open access
Semantic Scholar
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa
G. Lenz, M. Dreyling, E. Hoster, B. Wörmann +13 more
2005Journal of Clinical Oncology614 citations Open access
Semantic Scholar
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
T. Büchner, W. Berdel, C. Schoch, T. Haferlach +16 more
2006Journal of Clinical Oncology200 citations
Semantic Scholar
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
T. Haferlach, C. Schoch, H. Löffler, W. Gassmann +21 more
2003Journal of Clinical Oncology193 citations
Semantic Scholar
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C. Buske, E. Hoster, M. Dreyling, H. Eimermacher +16 more
2009Leukemia153 citations
Semantic Scholar
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
M. Stadler, U. Germing, K. Kliche, K. Josten +11 more
2004Leukemia147 citations
Semantic Scholar
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel +26 more
2007Blood99 citations
Semantic Scholar
Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea
R. Hehlmann, U. Berger, Markus Pfirrmann, A. Hochhaus +28 more
2003Leukemia86 citations Open access
Semantic Scholar
Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
O. Cornely, A. Böhme, D. Reichert, S. Reuter +18 more
2008Journal of Antimicrobial Chemotherapy72 citations
Semantic Scholar
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
M. Unterhalt, R. Herrmann, M. Tiemann, R. Parwaresch +15 more
1996Leukemia68 citations
Semantic Scholar
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia
W. Kern, G. Behre, T. Rudolf, Andrea Kerkhoff +6 more
1998Cancer62 citations Open access
Semantic Scholar
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
U. Krug, W. E. Berdel, R. Gale, C. Haferlach +30 more
2016Leukemia48 citations
Semantic Scholar
Treatment of older patients with AML.
T. Büchner, W. Berdel, B. Wörmann, C. Schoch +18 more
2005Critical reviews in oncology/hematology47 citations
Semantic Scholar
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia
N. Niederle, Dirk Megdenberg, L. Balleisen, W. Heit +6 more
2013Annals of Hematology40 citations
Semantic Scholar
Acute myeloid leukemia: treatment over 60.
T. Büchner, W. Hiddemann, W. Berdel, B. Wörmann +18 more
2002Reviews in Clinical and Experimental Hematology35 citations
Semantic Scholar
The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial
E. Hoster, M. Unterhalt, B. Wörmann, U. Duhrsen +10 more
200833 citations
Semantic Scholar
CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial
C. Binder, M. Ziepert, M. Pfreundschuh, U. Duhrsen +6 more
2013Annals of Hematology30 citations Open access
Semantic Scholar
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia
W. Kern, C. Aul, G. Maschmeyer, R. Kuse +7 more
1998Annals of Hematology28 citations
Semantic Scholar
Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.
M. Lübbert, B. Rüter, R. Claus, M. Schmid +11 more
200724 citations
Semantic Scholar
Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
C. Buske, M. Dreyling, H. Eimermacher, H. Boeck +15 more
200423 citations
Semantic Scholar
Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.
M. Lübbert, B. Rüter, M. Schmid, Sabine Knipp +10 more
200522 citations
Semantic Scholar
Chromosome aberrations are restricted to the CD56+, CD3− tumour cell population in natural killer cell lymphomas: a combined immunophenotyping and FISH study
Yan-Ming Zhang, Kit-Fai Wong, R. Siebert, P. Matthiesen +4 more
1999British Journal of Haematology21 citations
Semantic Scholar
Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months
C. Buske, E. Hoster, M. Dreyling, R. Forstpointner +16 more
200820 citations
Semantic Scholar
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
R. Hehlmann, H. Heimpel, D. Hossfeld, J. Hasford +18 more
1996Bone Marrow Transplantation20 citations
Semantic Scholar
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
T. Büchner, W. Hiddemann, S. Blasius, P. Koch +52 more
1990Haematology and blood transfusion20 citations
Semantic Scholar
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia
T. Büchner, U. Krug, R. Gale, A. Heinecke +25 more
2016Leukemia15 citations Open access
Semantic Scholar
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo
H. Löffrer, W. Gassmann, C. Jürgensen, J. Noak +17 more
1993Annals of Hematology12 citations
Semantic Scholar
Subgroup specific therapy effects in AML: AMLCG data.
T. Büchner, W. Hiddemann, W. Berdel, B. Wörmann +21 more
2004Annals of Hematology11 citations
Semantic Scholar
Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
V. Poeschel, M. Nickelsen, M. Hänel, S. Kremers +7 more
200610 citations
Semantic Scholar
Remission induction therapy: the more intensive the better?
T. Büchner, W. Hiddemann, W. Berdel, B. Wörmann +22 more
2001Cancer Chemotherapy and Pharmacology10 citations
Semantic Scholar
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
D. Niederwieser, Thomas Lang, R. Krahl, T. Heinicke +49 more
2023Annals of Hematology7 citations Open access
Semantic Scholar
Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.
T. Büchner, W. Berdel, C. Haferlach, S. Schnittger +27 more
20097 citations
Semantic Scholar
CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL.
L. Trumper, K. Hohloch, M. Kloess, U. Duhrsen +7 more
2006Journal of Clinical Oncology6 citations
Semantic Scholar
Older Age Is An Independent Risk Factor in AML
T. Büchner, W. Berdel, C. Haferlach, S. Schnittger +27 more
20085 citations
Semantic Scholar
The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)
H. Mueller, L. Nogova, D. Eichenauer, T. Halbsguth +7 more
20083 citations
Semantic Scholar
Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
J. Schubert, M. Ziepert, E. Lengfelder, M. Mohren +20 more
20073 citations
Semantic Scholar
The Role of Maintenance Chemotherapy, Immunotherapy, Induction Dose Reduction in Elderly Patients and Double Induction in the Treatment of Adult Acute Myeloid Leukemia. Four Randomized Studies of the AML Cooperative Group1
T. Büchner, W. Hiddemann, P. Koch, H. Pielken +43 more
19893 citations
Semantic Scholar
Final Analysis of Phase II Study of CHOP/CHOEP-14 Followed by Consolidation with Alemtuzumab in Untreated Aggressive T-Cell Lymphomas (DSHNHL 2003–1).
C. Binder, M. Ziepert, M. Loeffler, M. Pfreundschuh +6 more
20072 citations
Semantic Scholar
Failure of Fluconazole Prophylaxis to Reduce Mortality During Treatment for Refractory Acute Myeloid Leukemia: Results of a Phase III Multicenter Study
W. Kern, G. Behre, T. Rudolf, Andrea Kerkhoff +7 more
19982 citations
Semantic Scholar
Acute Myeloid Leukemia (AML): The Role of Maintenance Chemo- therapy
T. Büchner, W. Hiddemann, W. Berdel, B. Wörmann +24 more
20041 citations
Semantic Scholar
Treatment of Older Patients with Acute Myeloid Leukemia (AML)
T. Büchner, W. Hiddemann, C. Schoch, T. Haferlach +11 more
20011 citations
Semantic Scholar
[Carcinoembryonic antigen (CEA) and CEA-like activities in ascites and pleura-effusions (author's transl)].
H. Eimermacher, W. Tinnefeld, H. Pressler, P. Schuster +1 more
1979Klinische Wochenschrift1 citations
Semantic Scholar
Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity
T. Büchner, W. Berdel, U. Krug, C. Haferlach +22 more
20130 citations
Semantic Scholar
of the NHL-B2 trial of the DSHNHL the Treatment of Elderly Patients with Aggressive Lymphomas: Results 2-weekly or 3-weekly CHOP Chemotherapy with or without Etoposide for
N. Schmitz, C. Rudolph, M. Reiser, D. Hossfeld +5 more
20130 citations
Semantic Scholar
Assessment of age as its own risk factor in AML.
T. Büchner, W. Berdel, C. Haferlach, S. Schnittger +15 more
20120 citations
Semantic Scholar
Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups
T. Büchner, W. Berdel, U. Krug, C. Haferlach +15 more
20120 citations
Semantic Scholar
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial
U. Krug, C. Müller-Tidow, M. Stelljes, M. Sauerland +24 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

W. Hiddemann×24
Invite
W. Hiddemann — researcher profile on SciRah
T. Büchner×22
Invite
T. Büchner — researcher profile on SciRah
B. Wörmann×18
Invite
B. Wörmann — researcher profile on SciRah
L. Balleisen×17
Invite
L. Balleisen — researcher profile on SciRah

×17

Invite

M. Sauerland — researcher profile on SciRah

A. Heinecke×17

Invite

A. Heinecke — researcher profile on SciRah

E. Lengfelder×16

Invite

E. Lengfelder — researcher profile on SciRah

Invite

P. Staib — researcher profile on SciRah

T. Haferlach×15

Invite

T. Haferlach — researcher profile on SciRah

Invite

W. Ludwig — researcher profile on SciRah

Invite

W. Berdel — researcher profile on SciRah

Invite

C. Aul — researcher profile on SciRah